Navigation Links
ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Date:10/28/2009

as the additional non-cash interest expense recognized under the new accounting standard was offset by lower income tax expense. For the nine months ended September 30, 2008, the previously reported net income has been reduced by $2.3 million to $66.3 million. There was no impact on diluted earnings per share for either period as a result of adopting this new accounting method.

Operating Highlights

Cinryze net sales during the three and nine months ended September 30, 2009 were $29.1 million and $61.3 million, respectively. Vancocin net sales during the three and nine months ended September 30, 2009, decreased 22.0 percent to $51.4 million and 11.5 percent to $161.3 million, respectively due to lower sales volume, partially offset by the price increase in January 2009.

Cost of sales increased over the three and nine month periods in the prior year by $7.8 million and $21.5 million, respectively, due to the launch of Cinryze. In the comparative periods in 2008, the Company only had cost of sales related to Vancocin. As part of our October 2008 purchase of Lev, we acquired Cinryze inventory which was recorded at fair value in purchase accounting. This fair value of inventory increased cost of sales for Cinryze until all purchased inventory was sold to SP/SD's, with the final $0.7 million affecting cost of sales in the third quarter of 2009.

Investment in our commercialization efforts, product pipeline and the company continued to grow as research and development (R&D) and selling, general and administrative (SG&A) expenses in the third quarter 2009 were $31.2 million as compared to $29.1 million in the third quarter of 2008. R&D expenses decreased $3.8 million related primarily to discontinuing the maribavir prophylactic program, offset by costs associated with the initiation of our Phase 1 clinical trial for NTCD and costs related to the Cinryze Phase 4 safety requirement study for th
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
2. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
3. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
4. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
5. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
6. ViroPharma Announces Discontinuation of HCV-796 Development
7. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
8. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. ViroPharma to Present at the Natixis Bleichroeder Conference
10. ViroPharma to Present at Three Upcoming Healthcare Conferences
11. Accuray Incorporated to Present at 20th Annual Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... THOUSAND OAKS, Calif. , Sept. 2, 2015 ... announced the submission of a Marketing Authorization Application ... the centralized procedure for etelcalcetide (formerly AMG 416) ... adult patients with chronic kidney disease (CKD) on ... first calcimimetic agent that can be administered intravenously. ...
(Date:9/2/2015)... Miss. , Sept. 2, 2015   Gulf Coast Tattoo ... removal services with the cutting-edge Astanza Duality laser in ... unwanted ink erase their tattoo regret and take back control of ... but extends its services to Biloxi ... region. "With tattoo regret being as prevalent as it ...
(Date:9/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/6mlrvg/an_introduction ... "An Introduction to Medical Device Software: Regulations and ... conference to their offering. This ... regulations and requirements that apply to Medical Device ... real life examples and state-of- the-art practices identified ...
Breaking Medicine Technology:Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 6Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 7Gulf Coast Tattoo Removal Delivers Unrivaled Tattoo Removal Results To Biloxi And Gulfport With Astanza Duality 2An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2
... and CAMPBELL, Calif. , May ... sophisticated risk characterization and personalized therapy guidelines for ... of advanced tests, offering an accompanying nutrition program, ... Director stated:  "With appropriate risk characterization and treatment, ...
... May 25 The U.S. Food and Drug Administration approved Lumizyme (alglucosidase ... a rare genetic disorder. , , ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , , , ... an estimated 1 in every 40,000 to 300,000 births. Its primary symptom is ...
Cached Medicine Technology:Health Network Laboratories (HNL) Enters Into License Agreement With Hunter Laboratories to Provide HunterHeart Cardiovascular Disease Management Program. 2FDA Approves New Treatment for Late-Onset Pompe Disease 2FDA Approves New Treatment for Late-Onset Pompe Disease 3
(Date:9/2/2015)... DC (PRWEB) , ... September 03, 2015 , ... ... of nominations to determine who among America’s policymakers, public servants, activists, corporate executives, ... the nation’s health care. This year, that process led the magazine to tap ...
(Date:9/2/2015)... ... 02, 2015 , ... Chris Harrison of Harrison’s Footwear of Poulsbo announces the ... really,” says Chris. “We have a lot of repeat customers, and many of them ... for them—so we’ve given them the convenience of ordering from home.” , Harrison’s Footwear ...
(Date:9/2/2015)... ... 02, 2015 , ... Healthegy, a leading producer of conferences, ... will deliver keynote presentations at the upcoming Digital Healthcare Innovation Summit ( http://www.digitalhealthcaresummit.com/ ... , Larry Renfro, CEO of Optum, will deliver the morning address. In his ...
(Date:9/2/2015)... Los Angeles, CA (PRWEB) , ... September 02, 2015 , ... ... working to expand their fleet of truly superb luxury vehicles based on which of ... are pleased to announce the latest step forward in pursuit of this goal: a ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... the Abraham and Mildred Goldstein Charitable Trust to establish the Abraham and Mildred ... comes six months after WCHN recruited nationally known gynecologic oncologist Thomas J. Rutherford, ...
Breaking Medicine News(10 mins):Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:Harrison's Comfort Footwear Announces Expansion with New CHarrison Online Store 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:Luxury Line Auto Rental Announces Addition of the Rolls Royce Wraith to their Luxury Fleet 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 3
... is helping to increase understanding about normal vaginal biology ... women prone to infections and other diseases, and ... suffer from insidious health problems, including bacterial vaginosis and ... to seek medical treatment, said Larry Forney, a professor ...
... times as much food as conventional farming on the ... refute the long-standing assumption that organic farming methods cannot ... ,Researchers from the University of Michigan found that ... and conventional farms. In developing countries, food production could ...
... found that children with Tourettes syndromean inherited neurological disorder ... learn certain mental grammar skills much faster than their ... at Georgetown University Medical Center and the Kennedy Krieger ... linked to tics in Tourettes syndrome may also result ...
... of Havana have found that two compounds from lobster ... properties. ,The researchers said that the compounds could ... and antiseptic properties, as well as to increase growth ... a very common polymer present in nature as part ...
... Laboratories announced primary results for its large-scale clinical ... non-hormonal, non-prescription Zestra(R) Feminine Arousal Fluid for ... study, designed and managed by David M. Ferguson, ... parallel design trial intended to expand on the ...
... day, the Australian police finally announced that the Dr.Mohammed ... charged with providing reckless support to terrorists by ... ,His cousin Sabeel Ahmed 26, who worked at Halton ... of having information that could have helped police prevent ...
Cached Medicine News:Health News:Vaginal Bacteria Vary Among Healthy Women 2Health News:Organic Farming Can Feed the World 2Health News:Organic Farming Can Feed the World 3Health News:Tourettes Syndrome in Children may also Result in Superior Learning Skills 2Health News:Lobster Shells Have Great Healing and Antiseptic Properties 2Health News:Study Shows Positive Results for Zestra(R) Feminine Arousal Fluid 2Health News:Three Doctors Charged So Far in the UK Bombing Case 2Health News:Three Doctors Charged So Far in the UK Bombing Case 3Health News:Three Doctors Charged So Far in the UK Bombing Case 4
... flexible lighting products. The first is available ... sizes 5", 10", and 15" (refers to ... These lights are for use in procedures ... second group of flexible lights is our ...
These units, though small, still offer sufficient output to ensure current is fully adjustable from 0 to 70 mA. Instruction manual, ball electrodes, battery and leads with alligator clips are include...
These units, though small, still offer sufficient output to ensure current is fully adjustable from 0 to 70 mA. Instruction manual, ball electrodes, battery and leads with alligator clips are include...
... standby switch maintains power to the instrument without generating ... of 50 Hz separated by .75 s; repeats every ... Hz (2 pulses/s) , Tetanus: 50 Hz (50 ... pulses/2 s; repeats every 10 s , Output Current: ...
Medicine Products: